Chronic Lymphocytic Leukemia News and Research

RSS

Chronic Lymphocytic Leukemia (CLL) is the most common form of leukemia in adults. According to the American Cancer Society, approximately 8,000 patients will be diagnosed this year. More than 60,000 people in the U.S. currently have CLL. The disease arises in lymphocytes, a type of white blood cell that normally produces antibodies and serves important immune functions.

New approach may improve translation of immunological research findings

Mouse models have advanced our understanding of immune function and disease in many ways but they have failed to account for the natural diversity in human immune responses.

27 Jul 2017

New analysis compares emerging algorithms that look for cancer mutations

Sanford Burnham Prebys Medical Discovery Institute has undertaken the first-ever comparative analysis of a newly emerging category of algorithms that mine genetic information in cancer databases by focusing on internal gene structure (subgene resolution algorithms), in contrast to classical approaches that focus on genes treated as single units.

17 Jul 2017

Cord-blood-derived natural killer cells can be modified to destroy B-cell cancers

Immune cells with a general knack for recognizing and killing many types of infected or abnormal cells also can be engineered to hunt down cells with specific targets on them to treat cancer, researchers at The University of Texas MD Anderson Cancer Center report in the journal Leukemia.

13 Jul 2017

Adding new antibody to chemotherapy could bolster effects of cancer treatment

Adding an investigational antibody to the chemotherapy rituximab appears to restore its cancer-killing properties in certain leukemia patients with a natural resistance to the drug, according to a small, proof-of-concept study by Duke Cancer Institute researchers.

29 Jun 2017

New findings highlight possibility of developing specific cancer drugs with fewer side effects

Scientists at Karolinska Institutet in Sweden report that cancer cells and normal cells use different 'gene switches' in order to regulate the expression of genes that control growth.

6 Jun 2017

Combining oral drug with personalized cell therapy can lead to complete remission in CLL patients

Combining the kinase inhibitor ibrutinib with an investigational personalized cellular therapy known as CTL119 can lead to complete remission in patients with high-risk chronic lymphocytic leukemia (CLL), according to new research from the Perelman School of Medicine at the University of Pennsylvania and Penn's Abramson Cancer Center

31 May 2017

Cancer drug may help treat food allergies

A cancer drug for patients with certain types of leukemia and lymphoma can also prevent reactions to some of the most common airborne allergies, according to a recent Northwestern Medicine study. The promising data from this pilot study could have greater implications for adults with food allergies.

22 May 2017

WHO to launch pilot project for prequalifying biosimilar cancer medicines

This year WHO will launch a pilot project for prequalifying biosimilar medicines, a step towards making some of the most expensive treatments for cancer more widely available in low- and middle-income countries.

8 May 2017

Scientists announce ‘outstanding’ results of new blood cancer study

Scientists have described new results of a blood cancer study as 'outstanding' in tackling previously untreatable forms of chronic lymphocytic leukemia.

27 Apr 2017

Study explains how genetic mutations linked to telomere capping complex contribute to cancers

Scientists at The Wistar Institute have unveiled part of the protein complex that protects telomeres-;the ends of our chromosomes. The study, published online in Nature Communications, explains how a group of genetic mutations associated with this protein complex contributes to various cancers.

10 Apr 2017

Dietary anti-cancer compound from broccoli may work by influence on long non-coding RNAs

Researchers have discovered one of the reasons why broccoli may be good for your health.

16 Mar 2017

Study reveals novel mutations in mucosal melanoma that may pave way for new therapies

Not all melanomas are created equal. While most melanomas appear on the skin as the result of sun exposure, a small subset of melanomas arise spontaneously from mucosal tissues.

15 Mar 2017

New NCCN patient guide for Waldenström's Macroglobulinemia helps make informed treatment decisions

A very rare sub-type of Non-Hodgkin's Lymphoma, Waldenström's Macroglobulinemia affects approximately 1,500 - 2,000 people in the United States each year. While it is not curable, Waldenström's Macroglobulinemia is slow growing, and in many patients, manageable as a chronic disease.

6 Feb 2017

Enzyme identified in baker's yeast can efficiently annihilate leukemia cells

An enzyme identified in Saccharomyces cerevisiae, commonly known as brewer's or baker's yeast, has passed in vitro trials, demonstrating its capacity to kill acute lymphoblastic leukemia (ALL) cells.

18 Jan 2017

NCCN publishes new easy-to-understand patient education resources focused on brain cancer

The National Comprehensive Cancer Network has published the NCCN Guidelines for Patients and NCCN Quick Guide sheets for Brain Cancer - Gliomas—the first in a series of patient education resources focused on Brain Cancer.

10 Jan 2017

Swedish researchers develop new, low-cost method to examine individual leukemia cells

Leukemia is a disease in which each cell can exhibit different genetic traits, and now Swedish researchers have found a cheap way to examine the individual cells. Reported in Nature Communications, the breakthrough could transform leukemia treatment.

14 Oct 2016

NCCN publishes new resources to help patients understand treatment options for stomach cancer

This year, it is estimated that more than 26,000 people will be diagnosed with Stomach Cancer in the United States, with nearly one million new cases diagnosed worldwide each year.

4 Oct 2016

Right dose of CAR T cells and lymphodepletion can achieve good response rates for NHL patients

In a paper published today in Science Translational Medicine, researchers from Fred Hutchinson Cancer Research Center shared data from an early-phase study of patients with advanced non-Hodgkin lymphoma (NHL) who received JCAR014, a Chimeric Antigen Receptor (CAR) T cell treatment, and chemotherapy.

9 Sep 2016

BCL-2 inhibitor shows promise in AML patients

Patients whose acute myelogenous leukemia (AML) had relapsed or was resistant to chemotherapy and those who were deemed unable to tolerate chemotherapy experienced responses to the selective BCL-2 inhibitor venetoclax (Venclexta), with complete remissions in some, according to phase II clinical trial data.

12 Aug 2016

T-cell technology could be used to treat ovarian tumors with no adverse effects

With only incremental improvements in ovarian cancer survival over the last 40 years, there is a clear need for new treatment options with long-lasting results. Many researchers have turned toward the development of immunotherapies that direct T-cells to selectively eliminate ovarian tumor cells, but an appropriate therapeutic target for ovarian cancers has remained elusive.

29 Jul 2016